LIXTE Biotechnology regains Nasdaq equity compliance after $6.5M capital raise

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Received Nasdaq hearings panel notice of compliance with Listing Rule 5550(b)(1) requiring min $2.5M equity.
Compliance achieved after closing $5.0M placement (July 2) and $1.5M direct offering (July 8).
Subject to Panel Monitor through July 15, 2026; further deficiency triggers immediate hearing requirement.
CEO states regaining compliance underscores financial health as clinical trials progress in ovarian, colon, sarcoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.